Subcutaneously administered apomorphine: Pharmacokinetics and metabolism

Neurology

Volumn 62, Issue 6 SUPPL. 4, 2004, Pages

  LeWitt, Peter A ^a  

^a Clinical Neuroscience Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; CATECHOL METHYLTRANSFERASE; DOPAMINE RECEPTOR STIMULATING AGENT;

AREA UNDER THE CURVE; BODY FAT; BODY TEMPERATURE; DEMETHYLATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG UPTAKE; ENZYME ASSAY; FIRST PASS EFFECT; GLUCURONIDATION; HUMAN; INJECTION SITE; LIVER METABOLISM; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SULFATION;

EID: 1842523189     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.62.6_suppl_4.s8     Document Type: Review

References (38)

1. Poewe W, Wenning, GK. Apomorphine: an underutilized therapy for Parkinson's disease. Mov Disord 2000;15:789-794.
2. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951;76:252-255.
3. Cotzias GC, Papavasilious PS, Fehling C, Kaufman B, Mena I. Similarities between neurological effects of L-dopa and apomorphine. N Engl J Med 1970;282:31-33.
4. Stibe CM, Kempster PA, Lees AJ, Stern GM. Subcutaneous apomorphine in Parkinsonian on-off fluctuations. Lancet 1988;1:403-406.
5. Hardie RRJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain 1984;107:487-506.
6. LeWitt PA. Extending the action of levodopa's effects. In: LeWitt PA, Oertel WH, eds. Parkinson's disease: the treatment options. London: Martin Dunitz Publishers, 1999;141-158.
7. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576.
8. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002;17:1235-1241.
9. Pollak P, Champay AS, Gaio JM, Hommel M, Benabid AL. Subcutaneous apomorphine in Parkinson's disease. Rev Neurol 1990;146:116-122.
10. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine infusional in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
11. Chaudhuri KR, Critchley P, Abbott RJ, Pye IF, Millac PA. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet 1998;2:1260.
12. Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol 1994;17:243-259.
13. Dewey RB, Hutton JT, LeWitt PA, Factor SA. A randomized double-blind placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian "off" states. Arch Neurol 2001;58:1385-1392.
14. Neumeyer JL, Lal S, Baldessarini RJ. Historical highlights of the chemistry, pharmacology, and early clinical uses of apomorphine. In: Gessa GL, Corsini GU, eds. Apomorphine and other dopaminomimetics. Basic pharmacology. Vol. 1. New York: Raven Press, 1981:1-17.
15. Hutchinson WD, Levy R, Dostrovsky JO, Lozano AM, Lang AE. Effects of apomorphine on globus pallidus neurons in Parkinsonian patients. Ann Neurol 1997;42:767-775.
16. Goldman ME, Kebabian J. Aporphine enantiomers: interactions with D1 and D2 dopamine receptors. Mol Pharmacol 1984;25:18-23.
17. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002;303:791-804.
18. 2-adrenoceptor. J Pharmacol Exp Ther 2002;303:805-814.
19. 2 receptor subtypes. J Pharmacol Exp Ther 2002;303:815-822.
20. van Laar T, van der Geest R, Danhof M. Future delivery systems for apomorphine in patients with Parkinson's disease. Adv Neurol 1999;80:535-544.
21. Manson AJ, Hanagasi H, Turner K, et al. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 2001;124:331-340.
22. Priano L, Albani G, Calderoni S, et al. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease. Neurol Sci 2002;23(suppl 2):S99-100.
23. van der Geest R, van Laar T, Gubbens-Stibbe JM, Bodde HE, Danhof M. Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. Pharmacol Res 1997;14:1804-1810.
24. Dewey RB, Marangore DM, Ahlskog JE. A double-blind placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. Mov Disord 1998;13:782-787.
25. Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989;26:232-238.
26. Nicolle E, Pollak P, Serre-Debeauvais F, et al. Pharmacokinetics of apomorphine in parkinsonian patients. Fund Clin Pharmacol 1993;7:245-252.
27. Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999;37:257-271.
28. Gervason CL, Pollak PR, Limousin P, Perret JE. Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease. Clin Neuropharmacol 1993;16:113-119.
29. van Laar T, Jansen EN, Essink AW, Neef C, Oosterloo S, Roos RA. A double-blind study of the efficacy of apomorphine and its assessment in "off"-periods in Parkinson's disease. Clin Neurol Neurosurg 1993;95:231-235.
30. Deffond D, Durif F, Tournilhax M. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes. J Neurol Neurosurg Psychiatry 1993;56:101-103.
31. Harder S, Baas H, Demisch L, Simon E. Dose response and concentration response relationship of patients with Parkinson's disease and end-of-dose akinesia. Int J Clin Pharmacol Ther 1998;36:355-362.
32. Hofstee DJ, Neef C, van Laar T, Jansen EN. Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses. Clin Neuropharmacol 1994;17:45-52.
33. Przedborski S, Levivier M, Raftopoulos C, Naini AS, Hildebrand J. Peripheral and central pharmacokinetics of apomorphine and its effect on dopaminergic metabolism in humans. Mov Disord 1995;10:28-36.
34. Gancher ST, Nutt JG, Woodward WR. Absorption of apomorphine by several routes in parkinsonism. Mov Disord 1991;6:212-216.
35. Østergaard L, Wetdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double-blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:681-687.
36. Sam E, Jeanjean AP, Maloteaux JM, Verbeke N. Apomorphine pharmacokinetics after intranasal and subcutaneous application. Eur J Drug Metab Pharmacokinet 1995;1995;20:27-33.
37. van Laar T, Neef C, Danhof M, Roon KI, Roos RA. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease. Mov Disord 1996;11:633-638.
38. van der Geest R, van Laar T, Kruger PP, et al. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. Clin Neuropharmacol 1998;21:159-168.